【摘要】 目的探讨帕罗西汀联合米氮平治疗难治性抑郁症的疗效和安全性。方法将56例难治性抑郁症患者分为两组,均口服帕罗西汀治疗,研究组在此基础上联合米氮平治疗,观察8周。于治疗前后采用汉密顿抑郁量表、汉密顿焦虑量表、副反应量表评定疗效和不良反应。结果治疗8周末研究组显效率为67.9%、总有效率为92.9%,对照组分别为25.0%、78.6%,研究组显效率显著高于对照组(P<0.01)。研究组不良反应发生率为35.7%,对照组为32.1%,两组比较差异无显著性(P>0.05)。结论 帕罗西汀联合米氮平治疗难治性抑郁症起效快,疗效显著,安全性高,优于单用帕罗西汀治疗。更多还原

【Abstract】 Objective To explore the efficacy and safety of paroxetine combined with mirtazapine in the treatment of treatment-resistant depression（TRD）.Methods Fifty-six TRD patients were divided into two groups taking orally paroxetine,on this basis research group was plus mirtazapine for 8 weeks.Before and after treatment efficacies were assessed with the Hamilton Depression Scale（HAMD） and Hamilton Anxiety Scale（HAMA） and adverse reactions with the Treatment Emergent Symptom Scale（TESS）.Results At the end of the 8^th week obvious and total effective rate were respectively 67.9%and 92.9%in research and 25.0%and 78.6%in control group,obvious effective rate was significantly higher in research than in control group（P<0.01）.The incidence of adverse reaction was respectively 35.7%in research and 32.1%in control group and had no significant group difference（P>0.05）.Conclusion Paroxetine combined with mirtazapine in the treatment of TRD takes effect more rapidly and has an evident effect and higher safety compared with single paroxetine.更多还原